ALTERITY THERAPEUTICS LTD (ATHE)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Alterity Therapeutics Limited
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 1.96 | 2.05 | 1.89 | 1.96 | 13,410 |
| Nov 13, 2026 | 2.04 | 2.14 | 1.70 | 1.96 | 109,693 |
| Nov 12, 2026 | 2.28 | 2.28 | 2.04 | 2.10 | 71,750 |
| Nov 11, 2026 | 2.25 | 2.36 | 2.25 | 2.31 | 19,335 |
| Nov 10, 2026 | 2.46 | 2.50 | 2.29 | 2.32 | 16,190 |
| Nov 9, 2026 | 2.43 | 2.54 | 2.38 | 2.43 | 9,937 |
| Nov 6, 2026 | 2.35 | 2.45 | 2.35 | 2.43 | 13,430 |
| Nov 5, 2026 | 2.35 | 2.58 | 2.17 | 2.22 | 40,341 |
| Nov 4, 2026 | 2.47 | 2.65 | 2.37 | 2.44 | 131,498 |
| Nov 3, 2026 | 2.10 | 3.29 | 2.10 | 2.47 | 4,037,140 |
| Nov 2, 2026 | 2.17 | 2.23 | 2.09 | 2.09 | 6,062 |
| Oct 30, 2026 | 2.23 | 2.24 | 2.11 | 2.16 | 9,062 |
| Oct 29, 2026 | 2.25 | 2.25 | 2.16 | 2.23 | 3,790 |
| Oct 28, 2026 | 2.20 | 2.29 | 2.15 | 2.17 | 23,310 |
| Oct 27, 2026 | 2.14 | 2.24 | 2.02 | 2.14 | 3,527 |
| Oct 26, 2026 | 2.08 | 2.36 | 2.01 | 2.08 | 7,915 |
| Oct 23, 2026 | 2.12 | 2.43 | 2.04 | 2.09 | 26,791 |
| Oct 22, 2026 | 2.26 | 2.29 | 2.09 | 2.15 | 53,307 |
| Oct 21, 2026 | 2.44 | 2.62 | 2.30 | 2.39 | 56,523 |
| Oct 20, 2026 | 2.41 | 2.51 | 2.37 | 2.37 | 17,733 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Purchase | 47.6K | $23.8K | Aug 31, 2026 | |
| Director | Purchase | 47.6K | $23.8K | Aug 31, 2026 | |
| Chief Executive Officer | Purchase | 47.6K | $23.8K | Aug 31, 2026 | |
| Director | Grant/Award | 1.00M | -- | Jun 15, 2026 | |
| Director | Grant/Award | 2.00M | -- | Jun 15, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Stamler David Allen Chief Executive Officer, Director | 11.7M | 61.2% | FORM 4 |
Twin Lakes Capital Management, LLC | 139.3K | 0.7% | 13F |
GREENLEAF TRUST | 62.0K | 0.3% | 13F |
HB Wealth Management, LLC | 58.5K | 0.3% | 13F |
MORGAN STANLEY | 57.2K | 0.3% | 13F |
CITADEL ADVISORS LLC | 37.6K | 0.2% | 13F |
BNP PARIBAS FINANCIAL MARKETS | 15.3K | 0.1% | 13F |
XTX Topco Ltd | 11.8K | 0.1% | 13F |
RHUMBLINE ADVISERS | 2.0K | 0.0% | 13F |
ACADIAN ASSET MANAGEMENT LLC | 1.9K | 0.0% | 13F |
Insiders
- Marks Peter AshleyDirector
- Stamler David AllenChief Executive Officer
- Gozlan Lawrence BernardDirector
- Babarczy Julian MichaelDirector
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases.
Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease.
The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
based on 19.09M shares outstanding
30d Avg
223.46K
60d Avg
127.38K
90d Avg
90.61K
Signal8's dilution snapshot of ATHE as of Jun 30, 2026 records 1 outstanding warrant series, from SEC filings. 1 insider reported 1 open-market purchase of ATHE stock on Form 4 in the 90 days to Nov 17, 2026. Alterity Therapeutics Ltd (NASDAQ: ATHE) traded at $1.96 on Nov 16, 2026, unchanged from the previous close of $1.96. 52-week range: $1.70 to $5.89. The company is in the Healthcare sector (Biotechnology).